Kazia Therapeutics maintained at Buy as BTIG raises target
BTIG maintained Kazia Therapeutics at Buy and raised its price target to $40.00 per share from $34.00, according to Benzinga via TradingView News.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.